Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Reinthaller

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
British Journal of Cancer|September 17, 2014
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II studyJ Sehouli, A Reinthaller, C Marth, et al.
Cancer|January 28, 1998
Absence of p53 protein overexpression in precancerous lesions of the vulvaP D Kohlberger, R Kirnbauer, D Bancher, et al.
British Journal of Cancer|February 18, 2010
The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trialV Seebacher, S Polterauer, C Grimm, et al.
International Journal of Cancer|April 22, 1997
CD44 is an independent prognostic factor in early-stage cervical cancerP Speiser, C Wanner, C Tempfer, et al.
British Journal of Cancer|June 15, 2013
Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trialV Seebacher, G Hofstetter, S Polterauer, et al.
Journal of Computer Assisted Tomography|July 1, 1993
CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancerL Prayer, C Kainz, J Kramer, et al.
British Journal of Cancer|August 9, 2012
Nomogram prediction for overall survival of patients diagnosed with cervical cancerS Polterauer, C Grimm, G Hofstetter, et al.
Archives of Gynecology and Obstetrics|January 23, 2018
The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic OncologyA M Dueckelmann, D Fink, P Harter, et al.
Gynecologic Oncology|November 1, 1996
Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancerA Obermair, P Kohlberger, D Bancher-Todesca, et al.
Archives of Gynecology and Obstetrics|February 16, 2018
Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO SwitzerlandA M Dueckelmann, D Fink, P Harter, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
British Journal of Cancer|September 17, 2014
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II studyJ Sehouli, A Reinthaller, C Marth, et al.
Cancer|January 28, 1998
Absence of p53 protein overexpression in precancerous lesions of the vulvaP D Kohlberger, R Kirnbauer, D Bancher, et al.
British Journal of Cancer|February 18, 2010
The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trialV Seebacher, S Polterauer, C Grimm, et al.
International Journal of Cancer|April 22, 1997
CD44 is an independent prognostic factor in early-stage cervical cancerP Speiser, C Wanner, C Tempfer, et al.
British Journal of Cancer|June 15, 2013
Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trialV Seebacher, G Hofstetter, S Polterauer, et al.
Journal of Computer Assisted Tomography|July 1, 1993
CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancerL Prayer, C Kainz, J Kramer, et al.
British Journal of Cancer|August 9, 2012
Nomogram prediction for overall survival of patients diagnosed with cervical cancerS Polterauer, C Grimm, G Hofstetter, et al.
Archives of Gynecology and Obstetrics|January 23, 2018
The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic OncologyA M Dueckelmann, D Fink, P Harter, et al.
Gynecologic Oncology|November 1, 1996
Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancerA Obermair, P Kohlberger, D Bancher-Todesca, et al.
Archives of Gynecology and Obstetrics|February 16, 2018
Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO SwitzerlandA M Dueckelmann, D Fink, P Harter, et al.
Pageof 12